HIGHLIGHTS
- who: Ahmed N. Hegazy from the Germany Germany Germany Germany have published the article: Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia, in the Journal: (JOURNAL)
SUMMARY
The profound global health, social, economic disruption from COVID-19 continues. Various antibody-based vaccines and therapeutics can promote ADE, and while the extent to which ADE contributes to COVID19 immunopathology is still being evaluated, the possible clinical risks related to anti-SARS-CoV-2 antibody treatment remain unclear. Anti-SARS-CoV-2 antibodies casirivimab and imdevimab have been . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.